This preprint is under consideration at Journal of Gastrointestinal Cancer. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research Article
Touraj Asvadi Kermani
Tabriz University of Medical Sciences
Corresponding Author
ORCiD: https://orcid.org/0000-0001-6478-8624
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background
Colorectal cancer is one of the most common types of cancer worldwide. MiR-330 has been reported as a cell proliferation inhibitor by suppressing thymidylate synthase (TYMS) in FOLFOX, one of the major chemotherapy regimens used to treat colorectal cancers. A number of dysregulated miRNAs have been linked to CRC progression and treatment response and are thought to be promising prognostic biomarkers for this cancer. In the current study, miR-330, TYMS, and their interactions have been investigated in the absence of this chemotherapy to evaluate their therapeutic and diagnostic value for other treatment methods.
Material and Methods
The expression levels of miR-330 and TYMS were evaluated in-silico using TCGA datasets for colorectal cancer. Data validation was performed on a set of internal samples (100 pairs of CRC tumor specimens and adjacent non-cancerous samples) were determined utilizing RT-qPCR assay. The linkage between clinicopathological parameters and expression levels was also investigated.
Results
TCGA results illustrated that miR-330 and TYMS are significantly upregulated and downregulated through colorectal tumorigenesis, respectively. QRT-PCR results confirmed that the expression level of miR-330 was significantly higher in tumor tissues relative to margin tissues (p value = 0/0005) whereas TYMS was significantly down-regulated (p value = 0.0001). However, there was no significant association regarding TYMS and patient pathological features while miR-330 expression was associated with tumor stage and lymph node metastases.
Conclusion
The microRNA-330 inhibited cell proliferation by suppressing thymidylate synthase (TYMS) in colorectal cancer. Therefore, suggesting that they are valuable factors for further studies of alternative treatment and diagnostic methods.
Keywords
Colorectal Cancer, Real time PCR, TYMS, miR-330
Figure 1
Figure 2
Figure 3
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 12 May, 2021
No community comments so far
Editorial decision: Minor revision
On 21 Jul, 2021
Reviews received
Received 05 Jun, 2021
Reviewers invited
Invitations sent on 08 May, 2021
Editor assigned
On 06 May, 2021
First submitted
On 06 May, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
This preprint is under consideration at Journal of Gastrointestinal Cancer. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Touraj Asvadi Kermani
Tabriz University of Medical Sciences
Corresponding Author
ORCiD: https://orcid.org/0000-0001-6478-8624
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 12 May, 2021
No community comments so far
Editorial decision: Minor revision
On 21 Jul, 2021
Reviews received
Received 05 Jun, 2021
Reviewers invited
Invitations sent on 08 May, 2021
Editor assigned
On 06 May, 2021
First submitted
On 06 May, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background
Colorectal cancer is one of the most common types of cancer worldwide. MiR-330 has been reported as a cell proliferation inhibitor by suppressing thymidylate synthase (TYMS) in FOLFOX, one of the major chemotherapy regimens used to treat colorectal cancers. A number of dysregulated miRNAs have been linked to CRC progression and treatment response and are thought to be promising prognostic biomarkers for this cancer. In the current study, miR-330, TYMS, and their interactions have been investigated in the absence of this chemotherapy to evaluate their therapeutic and diagnostic value for other treatment methods.
Material and Methods
The expression levels of miR-330 and TYMS were evaluated in-silico using TCGA datasets for colorectal cancer. Data validation was performed on a set of internal samples (100 pairs of CRC tumor specimens and adjacent non-cancerous samples) were determined utilizing RT-qPCR assay. The linkage between clinicopathological parameters and expression levels was also investigated.
Results
TCGA results illustrated that miR-330 and TYMS are significantly upregulated and downregulated through colorectal tumorigenesis, respectively. QRT-PCR results confirmed that the expression level of miR-330 was significantly higher in tumor tissues relative to margin tissues (p value = 0/0005) whereas TYMS was significantly down-regulated (p value = 0.0001). However, there was no significant association regarding TYMS and patient pathological features while miR-330 expression was associated with tumor stage and lymph node metastases.
Conclusion
The microRNA-330 inhibited cell proliferation by suppressing thymidylate synthase (TYMS) in colorectal cancer. Therefore, suggesting that they are valuable factors for further studies of alternative treatment and diagnostic methods.
Figure 1
Figure 2
Figure 3
Loading...